Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Changes in Direct Healthcare Costs Before and After the Diagnosis of Inflammatory Bowel Disease: A Nationwide Population-Based Study.

Lee J, Im JP, Han K, Kim J, Lee HJ, Chun J, Kim JS.

Gut Liver. 2019 Jun 3. doi: 10.5009/gnl19023. [Epub ahead of print]

2.

The Cost of Inflammatory Bowel Disease: An Initiative From the Crohn's & Colitis Foundation.

Park KT, Ehrlich OG, Allen JI, Meadows P, Szigethy EM, Henrichsen K, Kim SC, Lawton RC, Murphy SM, Regueiro M, Rubin DT, Engel-Nitz NM, Heller CA.

Inflamm Bowel Dis. 2019 May 21. pii: izz104. doi: 10.1093/ibd/izz104. [Epub ahead of print]

PMID:
31112238
3.

Direct health-care cost utilization in Hong Kong inflammatory bowel disease patients in the initial 2 years following diagnosis.

Mak LY, Ng SC, Wong IOL, Li MKK, Lo FH, Wong MTL, Leung CM, Tsang SWC, Chan KH, Sze SF, Shan EHS, Lam BCY, Hui AJ, Hung IFN, Leung WK.

J Gastroenterol Hepatol. 2018 Jan;33(1):141-149. doi: 10.1111/jgh.13817.

PMID:
28475813
4.

Long-term evolution of direct healthcare costs for inflammatory bowel diseases: a population-based study (2006-2015).

Kim JW, Lee CK, Lee JK, Jeong SJ, Oh SJ, Moon JR, Kim HS, Kim HJ.

Scand J Gastroenterol. 2019 Apr;54(4):419-426. doi: 10.1080/00365521.2019.1591498. Epub 2019 Mar 24.

PMID:
30905222
5.

The Impact of Inflammatory Bowel Disease in Canada 2018: IBD in Seniors.

Nguyen GC, Targownik LE, Singh H, Benchimol EI, Bitton A, Murthy SK, Bernstein CN, Lee K, Cooke-Lauder J, Kaplan GG.

J Can Assoc Gastroenterol. 2019 Feb;2(Suppl 1):S68-S72. doi: 10.1093/jcag/gwy051. Epub 2018 Nov 2.

6.

Hospital costs, length of stay and prevalence of hip and knee arthroplasty in patients with inflammatory bowel disease.

Ehrenpreis ED, Zhou Y.

World J Gastroenterol. 2017 Jul 14;23(26):4752-4758. doi: 10.3748/wjg.v23.i26.4752.

7.

Costs of inflammatory bowel disease in Germany.

Stark R, König HH, Leidl R.

Pharmacoeconomics. 2006;24(8):797-814.

PMID:
16898849
8.

Risk of Anxiety and Depression in Patients with Inflammatory Bowel Disease: A Nationwide, Population-Based Study.

Choi K, Chun J, Han K, Park S, Soh H, Kim J, Lee J, Lee HJ, Im JP, Kim JS.

J Clin Med. 2019 May 10;8(5). pii: E654. doi: 10.3390/jcm8050654.

9.

Increased Risk of Diabetes in Inflammatory Bowel Disease Patients: A Nationwide Population-based Study in Korea.

Kang EA, Han K, Chun J, Soh H, Park S, Im JP, Kim JS.

J Clin Med. 2019 Mar 11;8(3). pii: E343. doi: 10.3390/jcm8030343.

10.

Emerging trends of inflammatory bowel disease in South Korea: A nationwide population-based study.

Kwak MS, Cha JM, Lee HH, Choi YS, Seo SI, Ko KJ, Park DI, Kim SH, Kim TJ.

J Gastroenterol Hepatol. 2019 Jun;34(6):1018-1026. doi: 10.1111/jgh.14542. Epub 2018 Dec 10.

PMID:
30447025
11.

Incidence and Treatment of Patients Diagnosed With Inflammatory Bowel Diseases at 60 Years or Older in Sweden.

Everhov ÅH, Halfvarson J, Myrelid P, Sachs MC, Nordenvall C, Söderling J, Ekbom A, Neovius M, Ludvigsson JF, Askling J, Olén O.

Gastroenterology. 2018 Feb;154(3):518-528.e15. doi: 10.1053/j.gastro.2017.10.034. Epub 2017 Nov 2.

PMID:
29102619
12.

Differences in healthcare expenditures for inflammatory bowel disease by insurance status, income, and clinical care setting.

Park MD, Bhattacharya J, Park K.

PeerJ. 2014 Sep 23;2:e587. doi: 10.7717/peerj.587. eCollection 2014.

13.

Increased end-stage renal disease risk in patients with inflammatory bowel disease: A nationwide population-based study.

Park S, Chun J, Han KD, Soh H, Choi K, Kim JH, Lee J, Lee C, Im JP, Kim JS.

World J Gastroenterol. 2018 Nov 14;24(42):4798-4808. doi: 10.3748/wjg.v24.i42.4798.

15.

Prevalence of inflammatory bowel disease in an insured population in Puerto Rico during 1996.

Torres EA, De Jesús R, Pérez CM, Iñesta M, Torres D, Morell C, Just E.

P R Health Sci J. 2003 Sep;22(3):253-8.

PMID:
14619451
16.

Market share and costs of biologic therapies for inflammatory bowel disease in the USA.

Yu H, MacIsaac D, Wong JJ, Sellers ZM, Wren AA, Bensen R, Kin C, Park KT.

Aliment Pharmacol Ther. 2018 Feb;47(3):364-370. doi: 10.1111/apt.14430. Epub 2017 Nov 22.

17.

Cost of illness of inflammatory bowel disease in the UK: a single centre retrospective study.

Bassi A, Dodd S, Williamson P, Bodger K.

Gut. 2004 Oct;53(10):1471-8.

18.

Direct and indirect healthcare resource utilization and costs associated with ulcerative colitis in a privately-insured employed population in the US.

Cohen R, Skup M, Ozbay AB, Rizzo J, Yang M, Diener M, Chao J.

J Med Econ. 2015 Jun;18(6):447-56. doi: 10.3111/13696998.2015.1021353. Epub 2015 Mar 27.

PMID:
25728698
19.

Use of pharmaceuticals by inflammatory bowel disease patients: a population-based study.

Metge CJ, Blanchard JF, Peterson S, Bernstein CN.

Am J Gastroenterol. 2001 Dec;96(12):3348-55.

PMID:
11774948
20.

Direct and Indirect Costs of Inflammatory Bowel Disease: Ten Years of Follow Up in a Danish Population-Based Inception Cohort.

Lo B, Vind I, Vester-Andersen MK, Bendtsen F, Burisch J.

J Crohns Colitis. 2019 May 10. pii: jjz096. doi: 10.1093/ecco-jcc/jjz096. [Epub ahead of print]

PMID:
31076743

Supplemental Content

Support Center